Breast Disease

Breast Disease

Cleveland Clinic’s Comprehensive Breast Cancer Program offers a multidisciplinary team of highly skilled specialists who provide comprehensive care to patients with breast cancer. A full array of services ranges from initial screening and diagnosis to high-risk genetic counseling to innovative breast cancer treatment and supportive therapies. Cleveland Clinic has 5 multidisciplinary comprehensive breast center locations: Fairview Hospital, Hillcrest Hospital, Beachwood Family Health Center, Strongsville Family Health Center, and Cleveland Clinic main campus. The Breast Centers at Cleveland Clinic’s main campus, Fairview Hospital, Beachwood Family Health Center, and Strongsville Family Health Center have been accredited by the American College of Surgeons’ National Accreditation Program for Breast Centers.

Percentage of Screening Mammograms Resulting in Callback

2013 - 2017

Cleveland Clinic offers a diagnostic callback program for patients with abnormal screening mammograms.

Needle Core or Fine Needle Aspirate Biopsy Prior to Surgical Treatment of Breast Cancerᵃ (N = 516)

2016

ᵃData from Cleveland Clinic tumor registry for main campus and family health center locations.

Cleveland Clinic's performance was 99.4% (513 of 516) in 2016 for this Commission on Cancer standard of care quality measure (95% confidence interval [CI], 98.3-99.9). Cleveland Clinic performs within the acceptable range for biopsy to surgical treatment of breast cancer.

Breast Conservation Surgery for Breast Cancer - Lumpectomy

2014 - 2017

Data are from Digestive Disease and Surgery Institute only

Breast Surgery for Breast Cancer - Mastectomy

2014 - 2017

All patients undergoing mastectomy are offered preoperative referral to plastic surgery.

Data includes all breast cancers plus prophylactic mastectomy with breast reconstruction.

Immediate Breast Reconstruction

2014 - 2017

Data are from Digestive Disease Surgery Institute only.

Five-Year Overall Survival of Female Patients With Breast Cancer by Estrogen Receptor, Progesterone Receptor, and HER2 Status (N= 6579)

2008-2016

Number at Risk Year 1 Year 2 Year 3 Year 4 Year 5
ER/PR Positive (N = 5130) 4502 3845 3074 2223 1439
HER2 Positive (N = 852) 759 594 470 308 134
Triple-Negative (N = 597) 503 365 263 167 67

ER= estrogen receptor, HER2= human epidermal growth factor receptor 2, PR= progesterone receptor

Five-Year Overall Survival of Female Patients With Stageᵃ 0 and I Breast Cancer (N= 4618)

2008-2016

Number at Risk Year 1 Year 2 Year 3 Year 4 Year 5
Stage 0 CC (N = 1376) 1291 1060 896 680 396
Stage I CC (N = 3242) 3017 2469 2008 1512 874

CC= Cleveland Clinic, NCDB= National Cancer Database

ᵃAJCC stage I-IV breast cancer

ᵇReference group data from the National Cancer Database (Commission on Cancer of the American College of Surgeons and the American Cancer Society) 2000-2002, as reported in: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer Science & Business Media; 2010.

Five-Year Overall Survival of Female Patients With Stageᵃ IIA and IIB Breast Cancer (N= 2143)

2008-2016

Number at Risk Year 1 Year 2 Year 3 Year 4 Year 5
Stage IIA (N = 1468) 1338 1124 935 715 424
Stage IIB (N = 675) 613 517 424 323 175

CC= Cleveland Clinic, NCDB= National Cancer Database

ᵃAJCC stage I-IV breast cancer

ᵇReference group data from the National Cancer Database (Commission on Cancer of the American College of Surgeons and the American Cancer Society) 2000-2002, as reported in: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer Science & Business Media; 2010.

Five-Year Overall Survival of Female Patients With Stageᵃ IIIA and IIIB Breast Cancer (N= 577)

2008-2016

Number at Risk Year 1 Year 2 Year 3 Year 4 Year 5
Stage IIIA (N = 446) 403 334 254 197 132
Stage IIIB (N = 131) 112 85 58 40 28

CC= Cleveland Clinic, NCDB= National Cancer Database

ᵃAJCC stage I-IV breast cancer

ᵇReference group data from the National Cancer Database (Commission on Cancer of the American College of Surgeons and the American Cancer Society) 2000-2002, as reported in: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer Science & Business Media; 2010.